Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer

Clinical Cancer Research

Volumn 3, Issue 9, 1997, Pages 1599-1608

  Hakimi, Janette M ^a   Schoenberg, Mark P ^a   Rondinelli, Rachel H ^a   Piantadosi, Steven ^a   Barrack, Evelyn R ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR;

ALLELE; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; DNA DETERMINATION; DNA POLYMORPHISM; HUMAN; HUMAN CELL; HYPOTHESIS; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

ADENOCARCINOMA; ALLELES; ANDROGENS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC VARIATION; HUMANS; LYMPHATIC METASTASIS; MALE; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RISK FACTORS; TRINUCLEOTIDE REPEATS; VARIATION (GENETICS);

EID: 0030873595     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Wingo, P. A., Tong, T., and Bolden, S. Cancer statistics, 1995. CA Cancer J. Clin., 45: 8-30, 1995.
2. Carter, H. B., and Coffey, D. S. Prostate cancer: the magnitude of the problem. In: D. S. Coffey, M. I. Resnick, F. A. Dorr, and J. P. Karr (eds.), A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer, pp. 1-7. New York: Plenum Publishing Corp., 1988.
3. Partin, A. W., Walsh, A. C., Pitcock, R. V., Mohler, J. L., Epstein, J. I., and Coffey, D. S. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. J. Urol., 142: 1254-1258, 1989.
4. Whitmore, W. F., Jr. The natural history of prostatic cancer. Cancer (Phila.), 32: 1104-1112, 1973.
5. Epstein, J. I., Carmichael, M. J., Partin, A. W., and Walsh, P. C. Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. J. Urol., 151: 1587-1592, 1994.
6. Carter, H. B., and Coffey, D. S. The prostate: an increasing medical problem. Prostate, 16: 39-48, 1990.
7. Oesterling, J. E. Prostate-specific antigen: a critical assessment of the most useful marker for adenocarcinoma of the prostate. J. Urol., 145: 907-923, 1991.
8. Wilding, G. The importance of steroid hormones in prostate cancer. Cancer Surv., 14: 113-130, 1992.
9. Nomura, A. M. Y., and Kolonel, L. N. Prostate cancer: a current perspective. Am. J. Epidemiol., 13: 200-227, 1991.
10. Ross, R. K., Paganini-Hill, A., and Henderson, B. E. The etiology of prostate cancer: what does the epidemiology suggest? Prostate, 4: 333-344, 1983.
11. Newmark, J. R., Hardy, D. O., Tonb, D. C., Carter, B. S., Epstein, J. I., Isaacs, W. B., Brown, T. R., and Barrack, E. R. Androgen receptor gene mutations in prostate cancer. Proc. Natl. Acad. Sci. USA, 89: 6319-6323, 1992.
12. 24→18) in the androgen receptor gene in human prostate cancer. Biochem. Biophys. Res. Commun., 198: 74-80, 1994.
13. Hakimi, J. M., Rondinelli, R. H., Schoenberg, M. P., and Barrack, E. R. Androgen receptor gene structure and function in prostate cancer. World J. Urol., 14: 329-337, 1996.
14. Simental, J. A., Sar, M., Lane, M. V., French, F. S., and Wilson, E. M. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J. Biol. Chem., 266: 510-518, 1991.
15. Jenster, G., van der Korput, H. A. G. M., Trapman, J., and Brinkmann, A. O. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J. Biol. Chem., 270: 7341-7346, 1995.
16. Zhou, Z-x., Lane, M. V., Kemppainen, J. A., French, F. S., and Wilson, E. M. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol. Endocrinol., 9: 208-218, 1995.
17. Langley, E., Zhou, Z-x., and Wilson, E. M. Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J. Biol. Chem., 270: 29983-29990, 1995.
18. Brown, C. J., Goss, S. J., Lubahn, D. B., Joseph, D. R., Wilson, E. M., French, F. S., and Willard, H. F. Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am. J. Hum. Genet., 44: 264-269, 1989.
19. La Spada, A. R., Wilson, E. M., Lubahn, D. B., Harding, A. E., and Fischbeck, K. H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature (Lond.), 352: 77-79, 1991.
20. Edwards, A., Hammond, H. A., Jin, L., Caskey, C. T., and Chakraborty, R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics, 12: 241-253, 1992.
21. Sleddens, H. F. B. M., Oostra, B. A., Brinkmann, A. O., and Trapman, J. Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum. Mol. Genet., 2: 493, 1993.
22. Macke, J. P., Hu, N., Hu, S., Bailey, M., King, V. L., Brown, T., Hamer, D., and Nathans, J. Sequence variation in the androgen receptor gene is not a common determinant of male sexual orientation. Am. J. Hum. Genet., 53: 844-852, 1993.
23. Zhang, L., Leeflang, E. P., and Arnheim, N. Studying human mutations by sperm typing: instability of CAG trinucleotide repeats in the human androgen receptor gene. Nat. Genet., 7: 531-535, 1994.
24. Watkins, W. S., Bamshad, M., and Jorde, L. B. Population genetics of trinucleotide repeat polymorphisms. Hum. Mol. Genet., 4: 1485-1491, 1995.
25. Irvine, R. A., Yu, M. C., Ross, R. K., and Coetzee, G. A. The CAG and CGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res., 55: 1937-1940, 1995.
26. Lubahn, D. B., Joseph, D. R., Sar, M., Tan, J-a., Higgs, H. N., Larson, R. E., French, F. S., and Wilson, E. M. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis, and gene expression in prostate. Mol. Endocrinol., 2: 1265-1275, 1988.
27. Chang, C., Kokontis, J., and Liao, S. Structural analysis of cDNA and amino acid sequences of human and rat androgen receptors. Proc. Natl. Acad. Sci. USA, 85: 7211-7215, 1988.
28. Faber, P. W., Kuiper, G. G. J. M., van Rooij, H. C. J., van der Korput, J. A. G. M., Brinkmann, A. O., and Trapman, J. The N-terminal domain of the human androgen receptor is encoded by one large exon. Mol. Cell. Endocrinol., 61: 257-262, 1989.
29. Tilley, W. D., Marcelli, M., Wilson, J. D., and McPhaul, M. J. Characterization and expression of a cDNA encoding the human androgen receptor. Proc. Natl. Acad. Sci. USA, 86: 327-331, 1989.
30. n-expanded neuronopathies. Hum. Mol. Genet., 4: 523-527, 1995.
31. Chamberlain, N. L., Driver, E. D., and Miesfeld, R. L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res., 22: 3181-3186, 1994.
32. Choong, C. S., Kemppainen, J. A., Zhou, Z-x., and Wilson, E. M. Reduced androgen receptor gene expression with first exon CAG repeat expansion. Mol. Endocrinol., 10: 1527-1535, 1996.
33. Brooks, B. P., and Fischbeck, K. H. Spinal and bulbar muscular atrophy: a trinucleotide-repeat expansion neurodegenerative disease. Trends Neurosci., 18: 459-461, 1995.
34. Sobue, G., Doyu, M., Morishima, T., Mukai, E., Yasuda, T., Kachi, T., and Mitsuma, T. Aberrant androgen action and increased size of tandem CAG repeat in androgen receptor gene in X-linked recessive bulbospinal neuronopathy. J. Neurolog. Sci., 121: 167-171, 1994.
35. Gerber, H-P., Seipel, K., Georgiev, O., Hofferer, M., Hug, M., Rusconi, S., and Schaffner, W. Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science (Washington DC), 263: 808-811, 1994.
36. Morgan, T. O., McCarthy, W. F., McLeod, D. G., Jacobsen, S. J., and Moul, J. W. Age-specific reference ranges for prostate-specific antigen (PSA) are higher in African American men. Proc. Am. Urol. Assoc., 155: 377A, 1996.
37. Morton, R. A., Jr. Racial differences in adenocarcinoma of the prostate in North American men. Urology, 44: 637-745, 1994.
38. Powell, I. J., Schwartz, K., and Hussain, M. Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans Affairs system. Urology, 46: 825-830, 1995.
39. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
40. Norremolle, A., Riess, O., Epplen, J. T., Fenger, K., Hasholt, L., and Sorensen, S. A. Trinucleotide repeat elongation in the Huntingtin gene in Huntington disease patients from 71 Danish families. Hum. Mol. Genet., 2: 1475-1476, 1993.
41. Alexander, R. B., Maguire, M. G., Epstein, J. I., and Walsh, P. C. Pathological stage is higher in older men with clinical stage B1 adenocarcinoma of the prostate. J. Urol., 141: 880-882, 1989.
42. Loeb, L. A. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res., 54: 5059-5063, 1994.
43. Bussemakers, M. J. G., Bova, G. S., Schoenberg, M. P., Hakimi, J. M., Barrack, E. R., and Isaacs, W. B. Microsatellite instability in human prostate cancer. J. Urol., 151: 469A, 1994.
44. Cunningham, J. M., Shan, A., Wick, M. J., McDonnell, S. K., Schaid, D. J., Tester, D. J., Qian, J., Takahashi, S., Jenkins, R. B., Bostwick, D. G., and Thibodeau, S. N. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res., 55: 5390-5395, 1995.
45. Sgrignoli, A. R., Walsh, P. C., Steinberg, G. D., Steiner, M. S., and Epstein, J. I. Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J. Urol., 152: 1077-1081, 1994.
46. Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I., and Walsh, P. C. The use of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110-114, 1993.
47. MacLean, H. E., Choi, W-T., Rekaris, G., Warne, G. L., and Zajac, J. D. Abnormal androgen receptor binding affinity in subjects with Kennedy's disease (spinal and bulbar muscular atrophy). J. Clin. Endocrinol. Metab., 80: 508-516, 1995.
48. McPhaul, M. J., Marcelli, M., Tilley, W. D., Griffin, J. E., Isidro-Gutierrez, R. F., and Wilson, J. D. Molecular basis of androgen resistance in a family with a qualitative abnormality of the androgen receptor and responsive to high-dose androgen therapy. J. Clin. Invest., 87: 1413-1421, 1991.
49. Jenster, G., de Ruiter, P. E., van der Korput, H. A. G. M., Kuiper, G. G. J. M., Trapman, J., and Brinkmann, A. O. Changes in the abundance of androgen receptor isotypes: effects of ligand treatment, glutamine-stretch variation, and mutation of putative phosphorylation sites. Biochemistry, 33: 14064-14072, 1994.
50. Beato, M., Chavez, S., and Truss, M. Transcriptional regulation by steroid hormones. Steroids, 61: 240-251, 1996.
51. Katzenellenbogen, J. A., O'Malley, B. W., and Katzenellenbogen, B. S. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell-and promoter-specific action of these hormones. Mol. Endocrinol., 10: 119-131, 1996.
52. Goodrich, J. A., Cutler, G., and Tjian, R. Contacts in context: promoter specificity and macromolecular interactions in transcription Cell, 84: 825-830, 1996.
53. Perutz, M. F., Johnson, T., Suzuki, M., and Finch, J. T. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. USA, 91: 5355-5358, 1994.
54. Stott, K., Blackburn, J. M., Butler, P. J. G., and Perutz, M. Incorporation of glutamine repeats makes protein oligomerize: implications for neurodegenerative diseases. Proc. Natl. Acad. Sci. USA, 92: 6509-6513, 1995.
55. Emili, A., Greenblatt, J., and Ingles, C. J. Species-specific interaction of the glutamine-rich activation domains of Sp1 with the TATA box-binding protein. Mol. Cell. Biol., 14: 1582-1593, 1994.
56. Schoenberg, M. P., Hakimi, J. M., and Barrack, E. R. Allele size distribution of the androgen receptor (AR) CAG microsatellite in human prostate cancer. Abstracts of the 8th Annual Meeting of the Society for Basic Urologic Research, San Francisco, California May 13-14, 1994.